You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Device for Ultra-Rapid Non-Pharmacologic Ocular Anesthesia

    SBC: Irenix Medical, Inc.            Topic: NEI

    PROJECT SUMMARY / ABSTRACTThe objective of this Phase II proposal is to further develop a novel device for ocular anesthesia based on thermo-electric cooling. Intravitreal injection therapy (IVT) is one of the most commonly performed procedures in all of medicine, with approximately 7 million injections in the USA in 2016. Ocular anesthesia is required, both for patient safety and for tolerability ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER

    SBC: DIAGNOLOGIX, LLC            Topic: NCI

    Chemotherapy may control but rarely cure metastatic cancers. Remarkably, modern immunotherapies, including cell-based therapies, have cured metastatic melanomas and other types of cancers. A major challenge for all cell therapies in general is the need to develop cost-effective and efficient manufacturing and delivery capabilities. We have recently established an innovative cell isolation technolo ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Prospective evaluation of a surgical solution for breast cancer-associated lymphedema

    SBC: Fibralign Corporation            Topic: 102

    Project Summary/Abstract Prospective evaluation of a surgical solution for breast cancer-associated lymphedema The proposed project will complete remaining key research and technology requirements that are needed to commercialize a ground-breaking interventional device for treating secondary lymphedema -- a chronic and debilitating disease that currently has no cure and impacts an estimated 15-30% ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Reverse Engineering Technical Data Packages for Development of Alternate Sources of Supply for DLA NSNs

    SBC: ENGINEERING AND SOFTWARE SYSTEM SOLUTIONS, INC.            Topic: DLA171002

    Maintaining the many types of weapons systems within the Department of Defense (DoD) is a tremendous task and procuring replacement components is made especially difficult due to obsolescence and often time, excessive pricing. Many components are no longer available from the Original Equipment Manufacturer (OEM) and the DoD does not have sufficient documentation to develop new suppliers. A new, s ...

    SBIR Phase I 2018 Department of DefenseDefense Logistics Agency
  5. Reverse Engineering Technical Data Packages for Development of Alternate Sources of Supply for DLA NSNs

    SBC: SAN DIEGO COMPOSITES, INC.            Topic: DLA171002

    San Diego Composites, Inc. (SDC) will provide the Defense Logistics Agency (DLA) qualified environmentally stable composite (ESC) replacement parts as an alternative source of supply for the parts on the DLA published Land and Maritime Replenishment Parts Purchase or Borrow and Limited Source Candidate Parts lists. SDCs ESC parts can be produced up to 75% faster, require up to 98% less preventativ ...

    SBIR Phase I 2018 Department of DefenseDefense Logistics Agency
  6. Develop Alternate Source of Supply for NSN 6130-015487556 Battery Charger

    SBC: SPECTRAL LABS INCORPORATED            Topic: DLA171002

    During Phase I, Spectral labs proposes using our multi-disciplined engineering, quality assurance, and production staff to reverse engineer an NSN 6130-015487556 Battery Charger, P/N RF-5853-CH106 in order to become an approved source. We will prepare a Source Approval Request (SAR) which includes a complete Technical Data Package and Test Plans. Following established ISO 9001 certified processes, ...

    SBIR Phase I 2018 Department of DefenseDefense Logistics Agency
  7. Increase Competition through Small Business Source Approval Aircraft Launch and Recovery Equipment (ALRE) Critical Safety/Critical Application Items (CSI/CAI)

    SBC: NEXTGEN AERONAUTICS, INC.            Topic: DLA172001

    NextGen Aeronautics (NextGen) is proposing to develop and submit Source Approval Requests (SARs) to increase competition for the manufacture and delivery of Aircraft Launch and Recovery Equipment (ALRE). The DLA has identified critical ALRA NSNs that are sourced by fewer than two manufacturers, limiting availability and competition. NextGen is a proven designer/manufacturer of high-complexity part ...

    SBIR Phase I 2018 Department of DefenseDefense Logistics Agency
  8. Topic 377: Bridging the Guideline Implementation Gap: Clinical Decision Support to Improve Cancer Symptom Management

    SBC: Cognitive Medical Systems, Inc.            Topic: NCI

    Advances in clinical research have yielded many evidence-based guidelines to help clinicians provide the right care for the right patient at the right time; however, studies suggest that nearly half the time, that care does not reach the patient. Clinical decision support (CDS) is an information technology-enabled method to identify missed opportunities and optimize care. This proposal seeks to sy ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Topic 371: Validation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation

    SBC: Riptide Bioscience, Inc.            Topic: NCI

    Radiotherapy, a key anticancer therapy, acts not only by killing cancer cells, but also by activating the body's immune system to attack the remaining cancer cells. However, the immune-stimulating effect is weakened by the tumor's capacity to reprogram immune cells, particularly macrophages, so that they instead actively promote tumor growth. RP-185 (Riptide Biosciences, Vallejo, CA),an engineered ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Topic 376: A noninvasive PET imaging strategy for longitudinal monitoring of immune contexture in the tumor microenvironmen

    SBC: CELLSIGHT TECHNOLOGIES, INC.            Topic: NCI

    Immunotherapy has transformed cancer treatment, but therapy response ranges between 5% to 60% depending on tumor and treatment type. Accumulating evidence points to number and type of immune cell infiltrates within tumors as the culprit for failure. To enable higher success rates, novel treatments aim to prime tumors for immunotherapy by improving the immune milieu within the tumor microenvironmen ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government